Agoracom Blog Home

Archive for the ‘Featured’ Category

AUGUSTA INDUSTRIES $AAO.ca Normal Course Issuer Bid (NCIB) A Winning Move After Lock-Up Agreement $PHO.ca $DYA.ca $OPS.ca

Posted by Er at 12:57 PM on Wednesday, November 22nd, 2017

Following the November 9th announcement of a Lock-Up Agreement for 32% of the company’s shares, Augusta has surprised the market announcing a NCIB whereas up to 17,340,061 common shares representing up to 10% of the Company’s public float will be purchased through an Agent and subsequently cancelled. Once again AAO is demonstrating its commitment to create shareholder value through the process of reducing the available shares on the open market.

Allen Lone, President and CEO of Augusta stated:

The Company believes that the purchase of the Shares will increase the proportionate interest of, and be advantageous to, all remaining security holders.”

Not only is this excellent news for existing shareholders, it could potentially lead a surge in price if recent examples of NCIB’s in the market are any indicator; especially considering the following are peers of AAO.v:

Spartan Energy (TSX SPE)

Announced NCIB buy back August 22nd when price was $5.11. It went as high as $7.37.                                         Spartan’s NCIB buy back was based on 5% of 175m outstanding or 8.7 million shares

 

 

Genworth MI Canada Inc  (TSX MIC)

Announced their NCIB buy back May 2nd when price was $34.45. Genworth went as high
as $44.81. Their NCIB buy back was based on 5% of 90.9m outstanding, equivalent to 4.59 million shares

 

 

Augusta Announces Normal Course Issuer Bid

Augusta Industries November 14th NCIB announcement for up to 17,340,061 common shares separates itself from its peers.  Not only is Augusta consuming for closure another 10% of the Company’s public float, it is sending a clear message to its current and prospective shareholders; the company is preparing itself for the market to take notice.  Augusta is removing more shares on a percentage basis at 10% than the 5% & 5% that  Spartan & Genworth each removed through their respective NCIB.

The AGM is December 29th

For more information about Augusta and the proposed Spin-Off, watch this interview with Allen Lone on AGORACOM.

ThreeD Capital $IDK.ca Appoints #Cryptocurrency Evangelist and Trader to Advisory Board #Bitcoin #Ethereum $HIVE.ca $BLOC.ca $CODE.ca

Posted by AGORACOM-JC at 9:27 AM on Wednesday, November 22nd, 2017

Threed capital

  • Mr. David Schirmer is a cryptocurrency enthusiast who spends most of his free time researching various topics in the blockchain/cryptocurrency space
  • Sheldon Inwentash, CEO of ThreeD comments, “David brings a vast knowledge of the blockchain/cryptocurrrency space through his research and enthusiasm for the sector.”

TORONTO, Nov. 22, 2017 — ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK) is pleased to announce the appointment of David Schirmer to its Advisory Board.

Mr. David Schirmer is a cryptocurrency enthusiast who spends most of his free time researching various topics in the blockchain/cryptocurrency space. He started his career in Tax Consulting at Deloitte before moving into the manufacturing industry with Saint Gobain (SGC) as a financial analyst and financial services manager. While at Saint Gobain, Mr. Schirmer was introduced to lean methodology. These principles help to methodically determine the value of various processes and outputs.

After a decade at SGC and lean manufacturing, Mr. Schirmer founded Nabu Consulting to apply those principles to startups using the lean methodology.  He began working with a blockchain-related project, which led him to analyzing every cryptocurrency that launched over the past two years. When it comes to analyzing the various cryptocurrency options available, Mr. Schirmer focuses on the fundamentals of the currency, rather than putting greater weight in the technical analysis. As such, Mr. Schirmer brings a detailed and analytical mindset to ThreeD’s blockchain/cryptocurrency advisory board.

Sheldon Inwentash, CEO of ThreeD comments, “David brings a vast knowledge of the blockchain/cryptocurrrency space through his research and enthusiasm for the sector.”

“It is a pleasure to join ThreeD Capital as an Advisor. I look forward in working with Sheldon and his Advisory Board in the amazing projects we can accomplish together,” stated David Schirmer.

About ThreeD Capital Inc.

ThreeD is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources, Artificial Intelligence and Blockchain sectors.

ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services, mentoring and access to the Company’s network in order to earn increases to the Company’s equity stake.

For further information:
Gerry Feldman, CPA, CA
Chief Financial Officer and Corporate Secretary
Feldman@threedcap.com
Phone: 416-606-7655

FEATURE: $GGX.ca Privately Held Golden Triangle Syndicate a Hidden Asset for Shareholder Appreciation $TUE.ca $MTB.ca $GTT.ca

Posted by Er at 2:01 PM on Tuesday, November 21st, 2017

 

GGX Gold – Pioneering B.C.’s Golden Triangle

 

GGX’s ownership in privately held Golden Triangle Syndicate may be the company’s best asset for shareholder appreciation

  • Owns 9% of Private Syndicate that is focused on project generation
  • Private Syndicate holds properties within B.C.’s famed Golden Triangle
  • GGX early to recognize massive exploration potential of the Golden Triangle area
  • Controls private projects with means to monetize when appropriate to shareholders.
  • Very tight share structure with 27M S/O and a 3.6$m M/C

 

 

Golden Triangle Syndicate Properties of Interest

 

  • Golddigger
  • Bingo
  • Monster
  • Giant
  • Goldengate
  • Goldridge
  • Motherlode
  • Bullion

 

 

To access more information on GGX Gold’s 9% interest, please click here: Private Syndicate

What I learned visiting my first live #Esports tournament $GMBL $ATVI $TTWO $GAME $EPY.ca

Posted by AGORACOM-JC at 9:36 AM on Monday, November 20th, 2017

  • The appeal of the live experience for most sports is obvious
  • For all the convenience of a televised game, it can’t compare to the sense of scale and 3D perspective you get actually seeing professional sports in person;
  • Watching plays develop and players perform nearly superhuman feats right in front of you.

Just watching on Twitch isn’t the same as being immersed in the crowd.

Kyle Orland – 11/19/2017, 10:00 AM

At this point, I don’t have much patience for the argument that eSports fans should stop watching other people play video games and just play those games themselves.

For one, it’s an argument that few people make about spectator sports like basketball and football, where the skill difference between a pro and a novice is roughly the same as in eSports. For another, the thrill of watching a competitor at the top of his or her game is entirely distinct (and better in some ways) from competing yourself.

ARS TRENDING VIDEO

Ars Live Episode 18: Gary Whitta explores geeky Hollywood

What I’ve never quite understood, though, is the concept of paying money for a ticket to watch a live eSports competition in-person.

The appeal of the live experience for most sports is obvious. For all the convenience of a televised game, it can’t compare to the sense of scale and 3D perspective you get actually seeing professional sports in person, watching plays develop and players perform nearly superhuman feats right in front of you.

None of that really applies in eSports, where you’re basically going to a large room to watch a big screen that has the exact same game content you could see at home on Twitch, down to the pixel. Watching the eSports competitors themselves as they sit like statues and become part of the machine during a match hardly seems worth the price of admission, either.

Yet plenty of people pay that admission. The League of Legends World Finals alone filled 80 to 90,000 seats in the Beijing National Stadium this year. What were these people seeing that I wasn’t?

To find out, I decided to check out the Rocket League Championship Series (RLCS) Season 4 world finals in nearby MGM National Harbor last weekend. What I quickly found out is that the point of being in a live eSports crowd is, to a large extent, just being part of the crowd.

Take a seat

Rocket League is by far my favorite eSport to watch as a spectator. While I can follow a high-level game of Hearthstone or Smash Bros. with the best of them, Rocket League‘s simple two-teams, two-goals format makes it incredibly simple for even a novice player to keep track of the action.

Watching a high-level Rocket League match, you get a real sense of the strategy and coordination necessary for the three-person teams to balance an offensive threat with the ability to rush back and knock a ball away on defense. And while pros make it look exceedingly simple to make precision passes and shots while rocketing at high speeds through the air, regular players know how hard it is to just make contact with a ball high above the arena.

I’ve only been a casual fan of the RLCS, checking out a few stray matches when my weekend schedule allows. Going into the finals weekend, I was at least peripherally aware of the stories surrounding competing teams like the robotically efficient Cloud 9 and the crowd-pleasing G2 eSports. I also knew that these hometown favorite North American teams were extreme underdogs to the European powerhouses like Method and Gale Force.

But it was something else to see a crowd of 3,000 react to those teams right in front of me, rather than just hearing their cheers through an ambient microphone via Twitch. In that National Harbor ballroom, the crowd itself practically became a participant in the competition, going crazy for the North American teams and icily silent for the European competition.

The competitors themselves almost faded into the background in this environment. Ghost Gaming player Zanejackey tried to get the crowd riled up at one point, standing and raising his arms above his head to get the noise pumping louder, but he received little to no notice for his efforts. While the crowd was treated to live webcam close-ups of the players at many points in the matches, the stony-faced videos may as well have been photographs.

What the crowd did react to was the action on those big projection screens. In tense overtime situations, the entire room swooned in crescendo with each shot and cried out in pain or glee with every close miss or solid goal. In quiet moments between matches, audience members might pick up a cheer of “Let’s go G2!” or try to get a wave going through the stands.

If I had been watching from my living room, I wouldn’t have heard the guy sitting behind me exclaim “it’s getting lit now, man!” after a big overtime goal. I wouldn’t have witnessed a neighbor literally jump up and slap his knee after a close crossbar miss.

I’m still not sure these kinds of moments are in and of themselves worth the significant money it costs to attend one of these events live. That said, I can now say I at least understand the potential appeal of sharing a dramatic eSports competition with a few thousands strangers.

Listing image by Kyle Orland

Source: https://arstechnica.com/gaming/2017/11/the-odd-appeal-of-watching-esports-live-and-in-person/

INTERVIEW: Tetra Bio-Pharma $TBP.ca Discusses Clinical Study for Smoked #Marijuana #CBD #MMJ $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:21 AM on Friday, November 17th, 2017

Tetra Bio-Pharma is no ordinary Medical Cannabis company. As a true Cannabis Bio-Pharma company, the company is the FIRST and ONLY pharmaceutical company in clinical trials for smoked marijuana, which is currently set to enter the valuable Phase 3 part of the trial.

AGORACOM Sat Down With President, Bernard Fortier To Discuss The Following:

1. How conducting clinical trials is massive differentiator from other companies.
2. The duration of Phase 3
3. The size of the market that will be available upon successful completion of Phase 3
4. How a successful Phase 3 can help solve the opioid crisis
5. Why the Company believes its’ inhalation device will generate $1.5M in revenue for Fiscal 2018
6. The Company’s distribution partnership with Aphria
7. Where the Medical Cannabis industry will be within 5 years

FEATURE: Glacier Lake Resources $GLI.ca Silver Vista Project Ready to Drill $JAX.ca $AMI.ca $GTT.ca $HBM.ca

Posted by Er at 2:00 PM on Thursday, November 16th, 2017

Why Glacier Lake Resources

Developing Silver Vista Project into Bulk Tonnage Silver & Copper

  • Glacier Lakes controls the Silver Vista project, a sediment hosted copper-silver deposit
  • Potential to host bulk tonnage silver mineralization.
  • Sediment-hosted copper deposits are a large and diverse group that includes some of the richest and larges deposits in the world
  • Silver Vista: Sedimentary Hosted Copper & Silver Deposit
  • 84M of historical 195g/t Silver & 3.65 g/t Copper at 193M depth
  • Sediment Hosted strata bound deposit
  • Prime target for Bulk Tonnage Silver & Copper deposit
  • Soil Geo-Chem survey outlined a 2.0KM by 1.5KM anomaly
  • Property has not been explored beyond an initial 1200 meter, 14 hole program
  • Drill program scheduled, results could be obtained as early as Q1/2018

 

 

 

https://glacierlake.ca/wp-content/uploads/2017/09/GLI_SilverVista_PPT09Sep2017.pdf

 

Successful Program on Seabridge’s $SA $SEA.ca Iron Cap Has Significant Implications For Both The KSM and Treaty Creek $SKE.ca $TUD.ca $PVG

Posted by AGORACOM-JC at 10:56 AM on Thursday, November 16th, 2017

Hublogolarge2 copy

  • Seabridge Gold just concluded a very successful program on their Iron Cap zone (bordering Treaty Creek) which confirms the report to be correct
  • Report predicted that the Iron Cap could be one of “B.C.’s next big deposits” and the recently concluded 2017 exploration program confirms that it is

November 16, 2017 

TSX-V:AMK

Cardston, Alberta

In 2014 a significant geological report (Kyba / Nelson) was published with a new geological understanding concerning the “mega deposits” found in B.C.’s Golden Triangle.  Seabridge Gold just concluded a very successful program on their Iron Cap zone (bordering Treaty Creek) which confirms the report to be correct.  The report predicted that the Iron Cap could be one of “B.C.’s next big deposits” and the recently concluded 2017 exploration program confirms that it is.  The report also predicted that Treaty Creek could be one of “B.C.’s next big deposits” and the 2017 exploration program initial results are confirming that is the case.  Co-author Jeff Kyba has left his position as Regional Geologist for the B.C. Ministry of Energy and Mines (Skeena division) and is now assisting in advancing Treaty Creek.

See how the successful Iron Cap program has significant implications for both the KSM and the Treaty Creek projects.

CLICK HERE

 

A summary of the Treaty Creek project can be viewed here: http://www.americancreek.com/images/pdf/Treaty_Creek_Joint_Venture_Project.pdf

The Treaty Creek Project is a joint venture between Tudor, Teuton Resources Corp., and American Creek. Tudor is the operator and holds a 60% interest with both American Creek and Teuton each holding respective 20% carried interests in the property (fully carried until a production notice is given).

About American Creek

American Creek holds a strong portfolio of gold and silver properties in British Columbia. The portfolio includes three “Golden Triangle” gold/silver properties; the Treaty Creek and Electrum joint ventures with Walter Storm/Tudor as well as the recently acquired 100% owned past producing Dunwell Mine group of properties. Other properties held throughout BC include the Gold Hill, Austruck-Bonanza, Ample Goldmax, Silver Side, and Glitter King.

For further information please contact Kelvin Burton at: Phone: 403 752-4040 or Email: info@americancreek.com. Information relating to the Corporation is available on its website at www.americancreek.com

ThreeD Capital Inc. $IDK.ca Acquires Securities of Global Cannabis Applications Corp. $APP.ca $PNP.ca $ZC.ca

Posted by AGORACOM-JC at 10:13 AM on Thursday, November 16th, 2017

Threed capital

  • Acquired ownership and control of an aggregate of 2,000,000 common shares and 2,000,000 common share purchase warrants of Global Cannabis Applications Corp. 
  • Represented approximately 3.7% of all issued and outstanding common shares of Global Cannabis

TORONTO, Nov. 16, 2017 – ThreeD Capital Inc. ( “ThreeD”) (CSE:IDK) is pleased to announce that it has acquired ownership and control of an aggregate of 2,000,000 common shares (the “Subject Shares”) and 2,000,000 common share purchase warrants (the “Subject Warrants” and together with the Subject Shares, the “Subject Units”) of Global Cannabis Applications Corp. (“Global Cannabis”) on November 15, 2017.  The Subject Units represented approximately 3.7% of all issued and outstanding common shares of Global Cannabis as of November 15, 2017 immediately following the transaction described above (or approximately 7.2% on a partially diluted basis, assuming exercise of the Subject Warrants only), resulting in a corresponding increase in the percentage of shares held by ThreeD and its Joint Actor as a result of the transaction.

Immediately before the transaction described above, ThreeD and the Joint Actor held an aggregate of 2,850,000 common shares of the Company (the “Pre-Closing Shares”), representing approximately 5.5% of the issued and outstanding common shares of the Company.  Of this total, ThreeD held an aggregate of 1,000,000 of the Pre-Closing Shares (representing approximately 1.9% of the issued and outstanding common shares of the Company), and the Joint Actor held an aggregate of 1,850,000 of the Pre-Closing Shares (representing approximately 3.6% of the issued and outstanding common shares of the Company).

Immediately following the transaction described above, ThreeD and the Joint Actor held an aggregate of 4,850,000 common shares (the “Post-Closing Shares”) and convertible securities entitling ThreeD and the Joint Actor to acquire an additional 2,000,000 common shares of the Company (the “Post-Closing Convertible Securities”), representing approximately 9.0% of the issued and outstanding common shares of the Company (or approximately 12.3% assuming exercise of such Post-Closing Convertible Securities only).  Of this total, ThreeD held an aggregate of 3,000,000 of the Post-Closing Shares and 2,000,000 of the Post-Closing Convertible Securities (representing approximately 5.6% of the issued and outstanding common shares of the Company, or approximately 9.0% assuming exercise of such Post-Closing Convertible Securities only), and the Joint Actor held an aggregate of 1,850,000 of the Post-Closing Shares and nil of the Post-Closing Convertible Securities (representing approximately 3.4% of the issued and outstanding common shares of the Company).

The Subject Units were acquired in a private placement and not through the facilities of any stock exchange.  The holdings of securities of Global Cannabis by ThreeD and the Joint Actor are managed for investment purposes, and ThreeD and the Joint Actor could increase or decrease their investments in Global Cannabis at any time, or continue to maintain their current investment position, depending on market conditions or any other relevant factor. The aggregate consideration payable for the Subject Units was $200,000, or $0.10 per Subject Unit.

The trade was effected in reliance upon the exemption contained in Section 2.3 of National Instrument 45-106 on the basis that each of ThreeD and the Joint Actor is an “accredited investor” as defined herein.

About ThreeD Capital Inc.

ThreeD Capital Inc. is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources, Artificial Intelligence and Blockchain sectors.

ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services, mentoring and access to the Company’s network in order to earn increases to the Company’s equity stake.

For further information:
Gerry Feldman, CPA, CA
Chief Financial Officer and Corporate Secretary
Feldman@threedcap.com
Phone: 416-606-7655

PyroGenesis $PYR.ca Announces $1.02 Million Sale of 2nd DROSRITE™ Furnace System to North American Automobile Parts Manufacturer $TSLA $DDD $SSYS $PRLB

Posted by AGORACOM-JC at 8:42 AM on Thursday, November 16th, 2017

Pyr header 1

  • Announced today that it has received a purchase order, in the amount of US$ 800,000 (Can$ 1.02 million), for the sale of a second DROSRITE™ Furnace System
  • Purchaser is a North American automobile parts manufacturer

MONTREAL, Nov. 16, 2017 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V:PYR) (OTCQB:PYRNF), a high-tech company (the “Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma waste-to-energy systems and plasma torch products, announces today that it has received a purchase order, in the amount of US$ 800,000 (Can$ 1.02 million), for the sale of a second (2nd) DROSRITE™ Furnace System (the “System”) to a North American automobile parts manufacturer (the “Client”).

The system is the second (2nd) commercial System sold to date and represents a re-order from the Client; the name of which remains confidential for competitive reasons. Delivery is scheduled to be in Q2-2018, and the contract calls for a fifty percent (50%) down payment and ten percent (10%) holdback.

PyroGenesis’ DROSRITE™ System is a salt-free, cost-effective, sustainable process for maximizing metal recovery from dross, a waste generated in the metallurgical industry. PyroGenesis’ patented process avoids costly loss of metal while reducing a smelter’s carbon footprint and energy consumption, providing an impressive return on investment.

“With aluminum manufacturers being subjected to increased pressure from regulatory authorities, requiring them to eliminate landfilling of hazardous salt cakes from traditional recovery operations, combined with tight operating margins, PyroGenesis’ DROSRITE™ System is able to (i) increase metal recovery from waste, without producing any hazardous by-products, while (ii) reducing operating costs,” said Mr. Pierre Carabin, Chief Technology Officer of PyroGenesis.

Additionally, as previously announced, PyroGenesis had received an unsolicited offer from a waste management company to be the sole distributor of PyroGenesis’ DROSRITE™ System within the Gulf Cooperation Council (the “GCC”). A successful DROSRITE™ demonstration was conducted at a major aluminum smelter, following which a formal visit took place at PyroGenesis’ facility in Montreal, Canada. Negotiations for the sale of DROSRITE™ Systems are currently underway.

Separately, a potential client from India has engaged PyroGenesis to perform a pilot demonstration at its manufacturer facility. The pilot system is currently being deployed to India for a demonstration scheduled in Q1-2018.

“PyroGenesis has recently hired a dedicated business development professional to address the growing demand for DROSRITE™,” said Massimo Dattilo, VP, Business Development of PyroGenesis. “Given our existing Client’s need for an additional 2 systems; combined with the continuing demand from the Middle East; and the fact that the Company’s demonstration unit is currently in-transit to India, all reflects, we believe, DROSRITE™’s success at addressing a serious need within the aluminum industry. The Company is currently targeting primary aluminum smelters in Asia and the Middle East where the market is estimated to be in excess of 1 million tonnes of dross1, as well as tertiary casting producers worldwide, all of which we expect will represent a potential requirement for DROSRITE™ systems numbering in the hundreds of units.”

“We expect DROSRITE™ to be a significant contributor to the operations of our non-additive business segments,” said Mr. P. Peter Pascali, President and CEO of PyroGenesis. “It underscores the success of our strategic plan in targeting high value niche problems in various industries. The fact that we have one of the largest concentrations of plasma expertise, under one roof, gives us the unique advantage of being able to target, and address, these opportunities.”

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc. is the world leader in the design, development, manufacture and commercialization of advanced plasma processes. PyroGenesis provides engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Its core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Its operations are ISO 9001:2008 certified, and have been ISO certified since 1997. PyroGenesis is a publicly-traded Canadian company on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace (Ticker Symbol: PYRNF). For more information, please visit www.pyrogenesis.com

 

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

 

Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTC Markets Group Inc. accepts responsibility for the adequacy or accuracy of this press release.

 

For further information: Rodayna Kafal, VP, Investor Relations and Communications, Phone: (514) 937-0002, E-mail: ir@pyrogenesis.com or rkafal@pyrogenesis.com

Tetra Bio-Pharma Inc. $TBP.ca Rx Princeps(TM) Now Available for Patients through Licensed Producer Partner Aphria $APH.ca $AERO $CBDS $CGRW $GBLX

Posted by AGORACOM-JC at 8:23 AM on Thursday, November 16th, 2017

Logo tetrabiopharma rgb web

  • Announced that Rx Princeps™, unique blend of dried medical cannabis used in its PPP001 clinical trials, is now available through licensed producer Aphria Inc.

OTTAWA, ONTARIO–(Nov. 16, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that Rx Princeps™, unique blend of dried medical cannabis used in its PPP001 clinical trials, is now available through licensed producer Aphria Inc. (“Aphria”) under Access to Cannabis for Medical Purposes Regulations (ACMPR).

Based on the most recent ACMPR market data from the Government of Canada, it is estimated that the sales of dried medical cannabis in Canada from April 2017 to March 2018 will be over $188M; Tetra is now entering this lucrative market and plans on progressively grabbing a significant share of it over the next two years. Mr Fortier, CEO of Tetra, stated last week “We are expecting to generate around $1.5 million in sales, in fiscal 2018 in our initial launch. Through our promotion and education efforts in Quebec, New Brunswick and part of Ontario, we estimate that over eight thousand patients will start using Rx Princeps™ under prescription from their doctors over in the next twelve months.”

Rx Princeps™ is a new option for doctors who want to prescribe medical cannabis. Prescribing Rx Princeps™ with the Rx Princeps™ inhalation device enables their patients to optimize the benefits of medical cannabis through the intake of a fixed dose of product, thereby ensuring consistency of treatment with a standardized high-quality product.

Aphria grows and produces medical cannabis under a strict quality management program. Tetra chose Aphria as its partner because their production processes were adopted from the highly restricted and regulated pharmaceutical industry, and go above and beyond cannabis industry regulations mandated by Health Canada. As a result, Aphria’s products are in line with the strict quality standards Tetra is establishing for the medical community and its patients.

200,000 patients are already registered under the ACMPR program and around 1.5 million adults in Canada suffer from chronic pain and are considered non-responders to opioids; medical cannabis could be a new therapeutic choice for those patients but physicians need bioavailability and safety data to prescribe medical cannabis with confidence. According to Health Canada, less than 3,000 physicians actually prescribe cannabis to their patients. Tetra is committed to provide them rigorous safety and bioavailability data. Tetra has begun educating pain clinics and the medical profession across Canada on Rx Princeps™, including its advantages for patients.

In Quebec, Tetra is working closely with Sante Cannabis in order to educate patients and support them in their medical journey with cannabis. Sante Cannabis is the first cannabinoid clinic and medical marijuana resource centre in Quebec.

About Rx Princeps™:

Rx Princeps™ is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD). Rx Princeps™ is composed of the same medical cannabis blend used to produce PPP001, which has demonstrated its safety in the Phase 1 clinical trial of PPP001. Patients who want to purchase Rx Princeps™ in Canada need a prescription from their physicians and to register with Licensed Producer Aphria.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; the success of the Rx Princeps product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
anne-sophie.courtois@tetrabiopharma.com
www.tetrabiopharma.com